🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Brandon T. Gufford

Wave 80 Biosciences (United States)

ORCID: 0000-0002-4772-9638

Also affiliated with Indiana University School of Medicine, Indiana University – Purdue University Indianapolis

Pharmacology, Toxicology and PharmaceuticsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.805Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies

Drug Metabolism and Disposition(2020)10.1124/dmd.120.000054
Top 25%
0.805DataRank
Top 25%27 citations

Brandon T. Gufford, Eric Chou, Marijanel Alilio, Sidney VanAlstine, Rachael E. Morley +4 more

Papers

Driven by 6 papers — median percentile 75. Top paper: “A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies”.

A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies

Drug Metabolism and Disposition(2020)10.1124/dmd.120.000054
Top 25%
0.805DataRank
Top 25%27 citations

Brandon T. Gufford, Eric Chou, Marijanel Alilio, Sidney VanAlstine, Rachael E. Morley +4 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200
N/A
0.612DataRank · unranked
12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers

Journal of Pharmacology and Experimental Therapeutics(2022)10.1124/jpet.122.001277
N/A
0DataRank · unranked
9 citations

Ingrid F. Metzger, Nadia O. Bamfo, Eric A. Benson, Andrea R. Masters, Jessica Bo Li Lu +2 more

The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial

The Pharmacogenomics Journal(2023)10.1038/s41397-023-00315-w
N/A
0DataRank · unranked
15 citations

Marc B. Rosenman, Pengyue Zhang, Cathy R. Fulton, John T. Callaghan, Ann Holmes +16 more

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers

Clinical Pharmacology & Therapeutics(2024)10.1002/cpt.3391
N/A
0DataRank · unranked
34 citations

Jeffrey T. Guptill, Michelle Mack, Marni Peterson, Stephen J. Byard, Robert J. Twieg +36 more

The strong clinical interaction between bupropion and CYP2D6 is primarily mediated through bupropion metabolites and their stereoisomers: A paradigm for evaluating metabolites in drug-drug interaction risk

Drug Metabolism and Disposition(2025)10.1016/j.dmd.2025.100070
N/A
0DataRank · unranked
1 citations

Amir Rashidian, Brandon T. Gufford, Jessica Bo Li Lu, Zeruesenay Desta, Irin Tanaudommongkon